全文获取类型
收费全文 | 292877篇 |
免费 | 46739篇 |
国内免费 | 11363篇 |
专业分类
耳鼻咽喉 | 6584篇 |
儿科学 | 7700篇 |
妇产科学 | 3092篇 |
基础医学 | 11492篇 |
口腔科学 | 4106篇 |
临床医学 | 44282篇 |
内科学 | 59185篇 |
皮肤病学 | 8971篇 |
神经病学 | 18012篇 |
特种医学 | 12322篇 |
外国民族医学 | 1篇 |
外科学 | 54151篇 |
综合类 | 40942篇 |
现状与发展 | 107篇 |
预防医学 | 24128篇 |
眼科学 | 4982篇 |
药学 | 18779篇 |
202篇 | |
中国医学 | 14219篇 |
肿瘤学 | 17722篇 |
出版年
2024年 | 1131篇 |
2023年 | 6493篇 |
2022年 | 5565篇 |
2021年 | 8575篇 |
2020年 | 11008篇 |
2019年 | 4783篇 |
2018年 | 10164篇 |
2017年 | 11330篇 |
2016年 | 11363篇 |
2015年 | 13833篇 |
2014年 | 22643篇 |
2013年 | 24668篇 |
2012年 | 18578篇 |
2011年 | 19544篇 |
2010年 | 23333篇 |
2009年 | 26018篇 |
2008年 | 17757篇 |
2007年 | 15522篇 |
2006年 | 16616篇 |
2005年 | 11550篇 |
2004年 | 8748篇 |
2003年 | 6696篇 |
2002年 | 5716篇 |
2001年 | 7295篇 |
2000年 | 5615篇 |
1999年 | 4117篇 |
1998年 | 3818篇 |
1997年 | 3592篇 |
1996年 | 3503篇 |
1995年 | 3329篇 |
1994年 | 2062篇 |
1993年 | 1647篇 |
1992年 | 1427篇 |
1991年 | 1449篇 |
1990年 | 1087篇 |
1989年 | 1208篇 |
1988年 | 1044篇 |
1987年 | 882篇 |
1986年 | 920篇 |
1985年 | 733篇 |
1984年 | 563篇 |
1983年 | 531篇 |
1982年 | 537篇 |
1981年 | 400篇 |
1980年 | 359篇 |
1979年 | 307篇 |
1978年 | 328篇 |
1977年 | 396篇 |
1975年 | 277篇 |
1972年 | 302篇 |
排序方式: 共有10000条查询结果,搜索用时 687 毫秒
11.
12.
13.
14.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
15.
16.
17.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
18.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
19.
目的研究慢阻肺急性加重期患者延迟就医与家庭动力学的相关性,希望能够为慢阻肺急性加重期患者拟定护理措施提供科学依据。方法选取2017年1月-2019年12月我院240例诊断为慢阻肺急性加重期的患者为研究对象。根据患者入院就医的时间进行分组,时间≥24h的延迟就医的患者为观察组,时间<24h的及时就医患者为对照组。结果两组患者在文化水平、家庭年收入、在职状态、医疗保险和婚姻状况和APACHEⅡ评分比较(P<0.05)。观察组患者疾病观念、个性化、系统逻辑和家庭氛围得分比对照组高(P<0.05)。Pearman的相关性分析结果显示:慢阻肺急性加重期患者延迟就医时间与各个层面分数以及家庭动力总分呈现负相关性(P<0.05)。应变量为延迟就医为应变量,患者的一般资料为自变量,经Logistic回归分析结果表明:延迟就医的影响因素为文化水平、家庭动力评分、职业状态、家庭收入、婚姻状况和APACHEⅡ评分。结论慢阻肺急性加重期患者家庭动力总分与疾病观念、个性化、系统逻辑和家庭氛围得分与延迟就医时间呈现负相关性,患者延迟就医的影响因素是家庭动力学评分。 相似文献
20.